caffeine + warfarin + omeprazole + metoprolol + midazolam (Galderma)

CYP 450 Substrates-Galderma R&D-atopic dermatitis refers to a specific cocktail of probe drugs—caffeine, warfarin, omeprazole, metoprolol, and midazolam—used in clinical research to evaluate the metabolic activity of Cytochrome P450 (CYP) enzymes. Specifically, this combination was employed by Galderma R&D in a Phase 2 open-label drug-drug interaction (DDI) study (NCT04921345) to investigate whether nemolizumab, an interleukin-31 receptor alpha (IL-31RA) antagonist, affects the pharmacokinetics of co-administered medications metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5. The study demonstrated that nemolizumab does not cause clinically significant changes in the exposure of these substrates, suggesting a low potential for CYP-mediated drug interactions in patients with moderate-to-severe atopic dermatitis.

Other names

CYP 450 SubstratesCYP450 SubstratesCYP-450 SubstratesCYP450 probe cocktailCYP-450 probe cocktailCYP 450 probe cocktailCYP450 index substratesCYP-450 index substratesCYP 450 index substratesCYP 450 Substrates-Galderma R&D-atopic dermatitis